Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346447 · ClinicalTrials.gov registry record
Effect of Baby Wipe Solutions on Fecal Enzyme-induced Irritation
A clinical trial, sponsored by Kimberly-Clark Corporation.
- Completed
- Registry status
- 23
- Enrollment target
NCT03346447: Completed study, sponsored by Kimberly-Clark Corporation.
NCT03346447 is a clinical trial that has completed, run by Kimberly-Clark Corporation. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03346447 has completed, sponsored by Kimberly-Clark Corporation.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
This is a single-center, prospective, single-blind pilot study to determine baby wipe formulations on an adult dermatitis model.
Primary Outcome
Time for a test site to reach an erythema score of ≥ 2.
Interventions
- OTHER Artificial Fecal Enzyme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2017-11-13 |
What the finished NCT03346447 record still lists
NCT03346447 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Artificial Fecal Enzyme is the first listed.
NCT03346447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03346447 about?
NCT03346447 is a clinical study titled "Effect of Baby Wipe Solutions on Fecal Enzyme-induced Irritation". This is a single-center, prospective, single-blind pilot study to determine baby wipe formulations on an adult dermatitis model.
What is the current status of trial NCT03346447?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2017-10-09. Estimated completion is 2017-11-13.
What interventions are being tested in trial NCT03346447?
The interventions under investigation include: Artificial Fecal Enzyme (OTHER).
Who is sponsoring clinical trial NCT03346447?
This trial is sponsored by Kimberly-Clark Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI